Contemporary management of phosphorus retention in chronic kidney disease: a review

Clinical and Experimental Nephrology

Volumn 19, Issue 6, 2015, Pages 985-999

  Amiri, Fateme Shamekhi ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic kidney disease; FGF 23; Hyperphosphatemia; Phosphate binders

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM CONTAINING PHOSPHATE BINDER; IRON BASED PHOSPHATE BINDER; LANTHANUM; MAGNESIUM; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; RESIN BASED BINDER; SALIVARY PHOSPHORUS BINDING AGENT; SEVELAMER; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23;

CHRONIC KIDNEY DISEASE; DIET RESTRICTION; GASTROINTESTINAL ABSORPTION; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; COMPLICATION; GENETICS; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; PHOSPHORUS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84951909013     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-015-1126-y     Document Type: Review

References (77)

1. Goldstein-Fuchs J, Fouque D. The ubiquitous nature and elusive role of phosphorus and vascular calcification. Am J Kidney Dis. 2009;2009(53):363–5.
2. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75(9):890–7.
3. Hutchison AJ. Oral phosphate binders. Kidney Int. 2009;75(9):906–14.
4. Friedman EA. Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int Suppl. 2005;95:S1–7.
5. Hofman-Bang J, Martusevicience G, Santini MA, Olgaard KA, Levin E. Increased parathyroid expression of klotho in uremic rats. Kidney Int. 2010;78(11):1119–27.
6. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF-23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408.
7. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, et al. FGF-23 neutralization improves chronic kidney disease-associated hyperthyroidism yet increases mortality. J Clin Invest. 2012;122(7):2543–53.
8. Yoda K, Imanishi Y, Yoda M, Mishima T, et al. Impaired response of FGF-23 to oral phosphate in patients with type 2 diabetes: a possible mechanism of atherosclerosis. J Clin Endocrinol Metab. 2012;97(11):1737–44.
9. Galassi A, Cupisti A, Santoro A, Cozzolino A. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool. J Nephrol. 2014. doi:10.1007/s40620-014-0142-4.
10. Ritz E, Hahn K, Ketteler M, kuhlmann MK, J Mann. Phosphate additives in food—a health risk. Dtsch Arztebl Int. 2012;109(4):49–55.
11. Ketteler M. Phosphate metabolism in CKD stages 3–5: dietary and pharmacological control. Int J Nephrol. 2011;2011:970245. doi:10.4061/2011/970245.
12. Guida B, Piccoli A, Trio R, Laccetti R, Nastasi A, Paglione A, et al. Dietary phosphate restriction in dialysis patients: a new approach for the treatment of hyperphosphatemis. Nutr Metab Cardiovasc Dis. 2011;21(11):879–84.
13. CS Shinaberger, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88(6):1511–8.
14. Carrero JJ, Cozzolino M. Nutritional therapy, phosphate control and renal protection. Nephron clin pract. 2014;126(1):1–7.
15. Covic A, Rastogi A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol. 2013;14:153.
16. Marks J, Churchill LJ, Srai SK, Biber J, Murer H, Jaeqer P, et al. Intestinal phosphate absorption in a model of chronic renal failure. Kidney Int. 2007;72(2):166–73.
17. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low and high calcium diets. Kidney Int. 2012;81(11):1112–22.
18. London G, Coyne D, Hruska K, Malluche HH, Martin KJ. The new kidney disease: improving global outcomes (KDIGO) guidelines—expert clinical focus on bone and vascular calcification. Clin Nephrol. 2010;74(6):423–32.
19. Sheikh MS, Maquire JA, Emmett M, Santa ana CA, Nicar MJ, Schiller LR, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989;83(1):66–73.
20. Cozzolino M, Urena-Torres P, Vervloet MG, Brandenburg V, Bover J, Goldsmith D, et al. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant. 2014;29(10):1815–20.
21. de Francisco MAL, Rodriquez M. Magnesium—its role in CKD. Nefrologia. 2013;33(3):389–99.
22. Liabeuf S, Okazaki H, Desjardines L, Fliser D, Goldsmith D, Covic A, et al. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant. 2014;29(7):1275–84.
23. Tzanakis I, Pras A, kounali D, Mamali V, Kartsonakis V, Mayopoulou-Symvoulidou D, et al. Mitral annular calcification in hemodialysis patients: possible protective role of magnesium. Nephrol Dial Transplant. 1997;12(9):2036–7.
24. Ishimura E, Okunu S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol. 2007;68(4):222–7.
25. Sakagushi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, IseKi K, et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One. 2014;9(12):e116273. doi:10.1371/journal.pone.116273.
26. Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7(6):578–89.
27. Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron. 1982;30(2):114–7.
28. Tzanakis IP, PaPadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE, et al. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol. 2008;40(1):193–201.
29. Covic A, Passlick-Deetjen J, Kroczak M, Buschges-Seraphin B, Ghenu A, Ponce P, et al. A comparison of calcium acetate/magnesium carbonate and sevelamer hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a collected, randomized study. Nephrol Dial Transplant. 2013;28(9):2383–92.
30. Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. Nephrol Dial Transplant Plus. 2008;1(3):135–47. doi:10.1093/ndtplus/sfn040.
31. Ferreira A, Frazao MJ, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, et al. Effects of Sevelamer HCL and ca carbonate on renal osteodystrophy in hemodialysis patients. Am Soc Nephrol. 2008;19(2):405–12. doi:10.1681/ASN.2006101089.
32. Perianayagam MC, Bertrand LJ. Endotoxin-binding affinity of Sevelamer HCL. Am J Nephrol. 2008;28(5):802–7. doi:10.1159/000135691.
33. Goto S, Fujii H, Kim JI, Fukagawa M. Homocysteine and folic acid levels in hemodialysis patients treated with Sevelamer hydrochloride. Clin Nephrol. 2010;73(6):420–5.
34. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, et al. Efficacy and tolerability of Sevelamer carbonate in hyperphosphatemia patients who have chronic kidney disease and are not on dialysis: mineral metabolism/bone disease. Clin J Am Soc Nephrol. 2008;3(4):1125–30.
35. Savica V, Santoro D, Monardo P, Mallamace A, Bellinghieri G. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag. 2008;4(4):821–6.
36. Sanai T, Tada H, Ono T, Fukumitsu T. Phosphate binders and metabolic acidosis in patients with undergoing maintenance hemodialysis-sevelamer hydrochloride, calcium carbonate, and Bixalomer. Hemodial Int. 2014. doi:10.1111/hdi.12188.
37. Hutchison AJ, Laville M. On behalf of the SPD405-313 lanthanum study group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008;23(11):3677–84.
38. Kazama JJ. Is lanthanum carbonate a safe drug? Clin Calcium. 2009;19(2):224–8.
39. Patrick CD, Goce BS, Aleksander S, Alastair H, Tony JF, Sylvie S, et al. A multicenter study on the effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003;85:S73–8.
40. Sprague SM. A comparative review of the efficacy and safety of established pi binders. Calcium, Sevelamer and lanthanum carbonate. Curr Med Res Opin. 2007;23(12):3167–75.
41. Torregrosa PV. Lanthanum carbonate in clinical practice. Nefrologia. 2008;28(Suppl 5):11–4.
42. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008;110(1):c15–23.
43. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve clin J Med. 2008;75(2):112–7.
44. Brambilla S, Vallaperta S, Graziani G, Montanelli A. Gadolinium and lanthanum: an iatrogenic transmetallation? Clin Biochem. 2008;41(13):1029–33.
45. John TD, Peter GB, Todd SI. Handbook of dialysis. Philadelphia: LWW; 2007. p. 594.
46. Leonard O, Spaak J, Goldsmith D. Regression of vascular calcification in chronic kidney disease-feasible or fantasy? A review of the clinical evidence. Br J Clin Pharmacol. 2013;76(4):560–72.
47. Evenepoel P. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int. 2008;74(3):265–75.
48. Grzegorzewska AE, Niepolski L. Calcimimetic drugs in stage 3–5 chronic kidney disease. Pol Merkur Lekareski. 2012;32(190):260–2.
49. Sabbagh Y, Schiavi SC. Role of NPT2b in health and chronic kidney disease. Curr Opin Nephrol Hypertens. 2014;23(4):377–84.
50. Lenglet A, Liabeuf S, Guffroy P, Brazier M, Massay ZA. Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R D. 2013;13(3):165–73.
51. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int. 2004;65(3):1099–104.
52. Tunara S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. PUMA-AG and HM74A are receptors for nicotinic acid and mediate its anti lipolytic effect. Nat Med. 2003;9(3):352–5.
53. Marshall BE, Donald BH, Kathryn BD, Garge R, Johnson C, Egan D, et al. Effects of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA. 2000;284(10):1263–70.
54. Kirchner S, Muduli A, Casirola D, Prum K, Douard V, Ferraris RP. Luminal fructose inhibits rat intestinal sodium phosphate co-transporter gene expression and phosphate uptake. Am J Clin Nutr. 2008;87(4):1028–38.
55. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN. Extended release nicotinic acid—a novel oral agent for phosphate control. Int Urol Nephrol. 2006;38(1):171–4.
56. Shin S, Lee S. Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients. Ther Clin Risk Manag. 2014;10:875–83.
57. Nastou D, Fernandez-fernandez B, Elewa U, Gonzalez-Espinoza L, Gonzalez-Parra E, Sanches-Nino MD, et al. Next-generation phosphate binders: focus on iron-based binders. Drugs. 2014;74(8):863–77.
58. Wuthrich RP, Chonchol M, Covic A, Gillard S, Chong E, Tumlin JA, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8:280–9.
59. Locatelli F, Dimkovic N, Pontoriero G, Spasovski G, Pljesa S, Kostic S, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in hemodialysis patients with hyperphosphatemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant. 2010;25(2):574–81.
60. Locatelli F, Spasovski G, Dimkovic N, Wanner C, Dellanna F, Pontoriero G. The effects of Colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphatemia: a 1-year prospective randomized study. Nephrol Dial Transplant. 2014;29(5):1061–73.
61. Eknoyan G. Salivary phosphorus binding: a novel approach to control hyperphosphatemia. J Am Soc Nephrol. 2009;20:460–2.
62. Savica V, Calo LA, Monardo P, Davis PA, Granata A, Santoro D, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol. 2009;20:639–44.
63. Akizawa T, Tsuruta Y, Okada Y, Miyauchi Y, Suda A, Kasahara H, et al. Effect of Chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial. BMC Nephrol. 2014;25(15):98.
64. Alessandro DC, Piccoli GB, Cupisti A. The “phosphorus pyramid”: a visual tool for dietary phosphate management in dialysis and CKD patients. BMC Nephrol. 2015;16(1):9 (20).
65. Cannata-Andía J, Torregrosa JV. Spanish nephrologists and the management of mineral and bone metabolism disorders in chronic kidney disease. Nefrologia. 2014;34(2):175–88.
66. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268–77.
67. Goto S, Komaba H, Moriwaki K, Fujimori A, Shibuya K, Nishioka M, et al. Clinical efficacy and costeffectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol. 2011;6:1375–84.
68. Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, et al. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health. 2011;14:1002–9.
69. Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome BA. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol Dial Transplant. 2014;29(11):2092–9.
70. Mudge DW, Johnson DW, Howley CM, Carmpell SE, Isbel NM, Van Eps CL, et al. Do aluminum-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol. 2011;12(20):1–8.
71. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1(4):697–703.
72. Friedman EA. Calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol. 2006;1(4):704–9.
73. Chertow GM, Burke SA, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245–52.
74. Block GA, Spiegel DM, Erlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815–24.
75. Bushinsky DA. phosphate binders: hold the calcium? Clin J Am Soc Nephrol. 2006;1(4):695–6.
76. Ahmed AH. Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. Ren Fail. 2010;32(5):642–6.
77. Ketteler M, Biggar PH, Liangos O. FGF 23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant. 2013;28(4):821–5.